 | • レポートコード：MRC2-11QY02087 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は急性リンパ芽球性白血病薬のグローバル市場について調査・分析したレポートです。種類別（経口、非経口）市場規模、用途別（病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別急性リンパ芽球性白血病薬の競争状況、市場シェア ・世界の急性リンパ芽球性白血病薬市場：種類別市場規模 2015年-2020年（経口、非経口） ・世界の急性リンパ芽球性白血病薬市場：種類別市場規模予測 2021年-2026年（経口、非経口） ・世界の急性リンパ芽球性白血病薬市場：用途別市場規模 2015年-2020年（病院、その他） ・世界の急性リンパ芽球性白血病薬市場：用途別市場規模予測 2021年-2026年（病院、その他） ・北米の急性リンパ芽球性白血病薬市場分析：米国、カナダ ・ヨーロッパの急性リンパ芽球性白血病薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの急性リンパ芽球性白血病薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の急性リンパ芽球性白血病薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの急性リンパ芽球性白血病薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Otsuka、Ono Pharmaceuticals、Amgen、Bristol-Myers Squibb、Novartis、Boehringer Ingelheim ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Acute Lymphoblastic Leukemia Drug Market
The global Acute Lymphoblastic Leukemia Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Acute Lymphoblastic Leukemia Drug Scope and Market Size
Acute Lymphoblastic Leukemia Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Acute Lymphoblastic Leukemia Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Acute Lymphoblastic Leukemia Drug market is segmented into
Oral
Parenteral
Segment by Application, the Acute Lymphoblastic Leukemia Drug market is segmented into
Hospital
Other medical institutions
Regional and Country-level Analysis
The Acute Lymphoblastic Leukemia Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Acute Lymphoblastic Leukemia Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Acute Lymphoblastic Leukemia Drug Market Share Analysis
Acute Lymphoblastic Leukemia Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Acute Lymphoblastic Leukemia Drug business, the date to enter into the Acute Lymphoblastic Leukemia Drug market, Acute Lymphoblastic Leukemia Drug product introduction, recent developments, etc.
The major vendors covered:
Otsuka
Ono Pharmaceuticals
Amgen
Bristol-Myers Squibb
Novartis
Boehringer Ingelheim
…
1 Study Coverage
1.1 Acute Lymphoblastic Leukemia Drug Product Introduction
1.2 Market Segments
1.3 Key Acute Lymphoblastic Leukemia Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Acute Lymphoblastic Leukemia Drug Market Size Growth Rate by Type
1.4.2 Oral
1.4.3 Parenteral
1.5 Market by Application
1.5.1 Global Acute Lymphoblastic Leukemia Drug Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Other medical institutions
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Acute Lymphoblastic Leukemia Drug Market Size, Estimates and Forecasts
2.1.1 Global Acute Lymphoblastic Leukemia Drug Revenue 2015-2026
2.1.2 Global Acute Lymphoblastic Leukemia Drug Sales 2015-2026
2.2 Global Acute Lymphoblastic Leukemia Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Acute Lymphoblastic Leukemia Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Acute Lymphoblastic Leukemia Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Acute Lymphoblastic Leukemia Drug Competitor Landscape by Players
3.1 Acute Lymphoblastic Leukemia Drug Sales by Manufacturers
3.1.1 Acute Lymphoblastic Leukemia Drug Sales by Manufacturers (2015-2020)
3.1.2 Acute Lymphoblastic Leukemia Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Acute Lymphoblastic Leukemia Drug Revenue by Manufacturers
3.2.1 Acute Lymphoblastic Leukemia Drug Revenue by Manufacturers (2015-2020)
3.2.2 Acute Lymphoblastic Leukemia Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Acute Lymphoblastic Leukemia Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Acute Lymphoblastic Leukemia Drug Revenue in 2019
3.2.5 Global Acute Lymphoblastic Leukemia Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Acute Lymphoblastic Leukemia Drug Price by Manufacturers
3.4 Acute Lymphoblastic Leukemia Drug Manufacturing Base Distribution, Product Types
3.4.1 Acute Lymphoblastic Leukemia Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Acute Lymphoblastic Leukemia Drug Product Type
3.4.3 Date of International Manufacturers Enter into Acute Lymphoblastic Leukemia Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Acute Lymphoblastic Leukemia Drug Market Size by Type (2015-2020)
4.1.1 Global Acute Lymphoblastic Leukemia Drug Sales by Type (2015-2020)
4.1.2 Global Acute Lymphoblastic Leukemia Drug Revenue by Type (2015-2020)
4.1.3 Acute Lymphoblastic Leukemia Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Acute Lymphoblastic Leukemia Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Acute Lymphoblastic Leukemia Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Acute Lymphoblastic Leukemia Drug Revenue Forecast by Type (2021-2026)
4.2.3 Acute Lymphoblastic Leukemia Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Acute Lymphoblastic Leukemia Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Acute Lymphoblastic Leukemia Drug Market Size by Application (2015-2020)
5.1.1 Global Acute Lymphoblastic Leukemia Drug Sales by Application (2015-2020)
5.1.2 Global Acute Lymphoblastic Leukemia Drug Revenue by Application (2015-2020)
5.1.3 Acute Lymphoblastic Leukemia Drug Price by Application (2015-2020)
5.2 Acute Lymphoblastic Leukemia Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Acute Lymphoblastic Leukemia Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Acute Lymphoblastic Leukemia Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Acute Lymphoblastic Leukemia Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Acute Lymphoblastic Leukemia Drug by Country
6.1.1 North America Acute Lymphoblastic Leukemia Drug Sales by Country
6.1.2 North America Acute Lymphoblastic Leukemia Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Acute Lymphoblastic Leukemia Drug Market Facts & Figures by Type
6.3 North America Acute Lymphoblastic Leukemia Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Acute Lymphoblastic Leukemia Drug by Country
7.1.1 Europe Acute Lymphoblastic Leukemia Drug Sales by Country
7.1.2 Europe Acute Lymphoblastic Leukemia Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Acute Lymphoblastic Leukemia Drug Market Facts & Figures by Type
7.3 Europe Acute Lymphoblastic Leukemia Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Acute Lymphoblastic Leukemia Drug by Region
8.1.1 Asia Pacific Acute Lymphoblastic Leukemia Drug Sales by Region
8.1.2 Asia Pacific Acute Lymphoblastic Leukemia Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Acute Lymphoblastic Leukemia Drug Market Facts & Figures by Type
8.3 Asia Pacific Acute Lymphoblastic Leukemia Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Acute Lymphoblastic Leukemia Drug by Country
9.1.1 Latin America Acute Lymphoblastic Leukemia Drug Sales by Country
9.1.2 Latin America Acute Lymphoblastic Leukemia Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Acute Lymphoblastic Leukemia Drug Market Facts & Figures by Type
9.3 Central & South America Acute Lymphoblastic Leukemia Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Acute Lymphoblastic Leukemia Drug by Country
10.1.1 Middle East and Africa Acute Lymphoblastic Leukemia Drug Sales by Country
10.1.2 Middle East and Africa Acute Lymphoblastic Leukemia Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Acute Lymphoblastic Leukemia Drug Market Facts & Figures by Type
10.3 Middle East and Africa Acute Lymphoblastic Leukemia Drug Market Facts & Figures by Application
11 Company Profiles
11.1 Otsuka
11.1.1 Otsuka Corporation Information
11.1.2 Otsuka Description and Business Overview
11.1.3 Otsuka Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Otsuka Acute Lymphoblastic Leukemia Drug Products Offered
11.1.5 Otsuka Related Developments
11.2 Ono Pharmaceuticals
11.2.1 Ono Pharmaceuticals Corporation Information
11.2.2 Ono Pharmaceuticals Description and Business Overview
11.2.3 Ono Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Ono Pharmaceuticals Acute Lymphoblastic Leukemia Drug Products Offered
11.2.5 Ono Pharmaceuticals Related Developments
11.3 Amgen
11.3.1 Amgen Corporation Information
11.3.2 Amgen Description and Business Overview
11.3.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Amgen Acute Lymphoblastic Leukemia Drug Products Offered
11.3.5 Amgen Related Developments
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Corporation Information
11.4.2 Bristol-Myers Squibb Description and Business Overview
11.4.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Bristol-Myers Squibb Acute Lymphoblastic Leukemia Drug Products Offered
11.4.5 Bristol-Myers Squibb Related Developments
11.5 Novartis
11.5.1 Novartis Corporation Information
11.5.2 Novartis Description and Business Overview
11.5.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Novartis Acute Lymphoblastic Leukemia Drug Products Offered
11.5.5 Novartis Related Developments
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Corporation Information
11.6.2 Boehringer Ingelheim Description and Business Overview
11.6.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Boehringer Ingelheim Acute Lymphoblastic Leukemia Drug Products Offered
11.6.5 Boehringer Ingelheim Related Developments
11.1 Otsuka
11.1.1 Otsuka Corporation Information
11.1.2 Otsuka Description and Business Overview
11.1.3 Otsuka Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Otsuka Acute Lymphoblastic Leukemia Drug Products Offered
11.1.5 Otsuka Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Acute Lymphoblastic Leukemia Drug Market Estimates and Projections by Region
12.1.1 Global Acute Lymphoblastic Leukemia Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Acute Lymphoblastic Leukemia Drug Revenue Forecast by Regions 2021-2026
12.2 North America Acute Lymphoblastic Leukemia Drug Market Size Forecast (2021-2026)
12.2.1 North America: Acute Lymphoblastic Leukemia Drug Sales Forecast (2021-2026)
12.2.2 North America: Acute Lymphoblastic Leukemia Drug Revenue Forecast (2021-2026)
12.2.3 North America: Acute Lymphoblastic Leukemia Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Acute Lymphoblastic Leukemia Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Acute Lymphoblastic Leukemia Drug Sales Forecast (2021-2026)
12.3.2 Europe: Acute Lymphoblastic Leukemia Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Acute Lymphoblastic Leukemia Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Acute Lymphoblastic Leukemia Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Acute Lymphoblastic Leukemia Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Acute Lymphoblastic Leukemia Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Acute Lymphoblastic Leukemia Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Acute Lymphoblastic Leukemia Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Acute Lymphoblastic Leukemia Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Acute Lymphoblastic Leukemia Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Acute Lymphoblastic Leukemia Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Acute Lymphoblastic Leukemia Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Acute Lymphoblastic Leukemia Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Acute Lymphoblastic Leukemia Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Acute Lymphoblastic Leukemia Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Acute Lymphoblastic Leukemia Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Acute Lymphoblastic Leukemia Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Acute Lymphoblastic Leukemia Drug Market Segments
Table 2. Ranking of Global Top Acute Lymphoblastic Leukemia Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Acute Lymphoblastic Leukemia Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Oral
Table 5. Major Manufacturers of Parenteral
Table 6. Global Acute Lymphoblastic Leukemia Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 7. Global Acute Lymphoblastic Leukemia Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 8. Global Acute Lymphoblastic Leukemia Drug Sales by Regions 2015-2020 (K Pcs)
Table 9. Global Acute Lymphoblastic Leukemia Drug Sales Market Share by Regions (2015-2020)
Table 10. Global Acute Lymphoblastic Leukemia Drug Revenue by Regions 2015-2020 (US$ Million)
Table 11. Global Acute Lymphoblastic Leukemia Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 12. Global Acute Lymphoblastic Leukemia Drug Sales Share by Manufacturers (2015-2020)
Table 13. Global Acute Lymphoblastic Leukemia Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 14. Global Acute Lymphoblastic Leukemia Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Acute Lymphoblastic Leukemia Drug as of 2019)
Table 15. Acute Lymphoblastic Leukemia Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 16. Acute Lymphoblastic Leukemia Drug Revenue Share by Manufacturers (2015-2020)
Table 17. Key Manufacturers Acute Lymphoblastic Leukemia Drug Price (2015-2020) (USD/Pcs)
Table 18. Acute Lymphoblastic Leukemia Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 19. Manufacturers Acute Lymphoblastic Leukemia Drug Product Type
Table 20. Date of International Manufacturers Enter into Acute Lymphoblastic Leukemia Drug Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Global Acute Lymphoblastic Leukemia Drug Sales by Type (2015-2020) (K Pcs)
Table 23. Global Acute Lymphoblastic Leukemia Drug Sales Share by Type (2015-2020)
Table 24. Global Acute Lymphoblastic Leukemia Drug Revenue by Type (2015-2020) (US$ Million)
Table 25. Global Acute Lymphoblastic Leukemia Drug Revenue Share by Type (2015-2020)
Table 26. Acute Lymphoblastic Leukemia Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 27. Global Acute Lymphoblastic Leukemia Drug Sales by Application (2015-2020) (K Pcs)
Table 28. Global Acute Lymphoblastic Leukemia Drug Sales Share by Application (2015-2020)
Table 29. North America Acute Lymphoblastic Leukemia Drug Sales by Country (2015-2020) (K Pcs)
Table 30. North America Acute Lymphoblastic Leukemia Drug Sales Market Share by Country (2015-2020)
Table 31. North America Acute Lymphoblastic Leukemia Drug Revenue by Country (2015-2020) (US$ Million)
Table 32. North America Acute Lymphoblastic Leukemia Drug Revenue Market Share by Country (2015-2020)
Table 33. North America Acute Lymphoblastic Leukemia Drug Sales by Type (2015-2020) (K Pcs)
Table 34. North America Acute Lymphoblastic Leukemia Drug Sales Market Share by Type (2015-2020)
Table 35. North America Acute Lymphoblastic Leukemia Drug Sales by Application (2015-2020) (K Pcs)
Table 36. North America Acute Lymphoblastic Leukemia Drug Sales Market Share by Application (2015-2020)
Table 37. Europe Acute Lymphoblastic Leukemia Drug Sales by Country (2015-2020) (K Pcs)
Table 38. Europe Acute Lymphoblastic Leukemia Drug Sales Market Share by Country (2015-2020)
Table 39. Europe Acute Lymphoblastic Leukemia Drug Revenue by Country (2015-2020) (US$ Million)
Table 40. Europe Acute Lymphoblastic Leukemia Drug Revenue Market Share by Country (2015-2020)
Table 41. Europe Acute Lymphoblastic Leukemia Drug Sales by Type (2015-2020) (K Pcs)
Table 42. Europe Acute Lymphoblastic Leukemia Drug Sales Market Share by Type (2015-2020)
Table 43. Europe Acute Lymphoblastic Leukemia Drug Sales by Application (2015-2020) (K Pcs)
Table 44. Europe Acute Lymphoblastic Leukemia Drug Sales Market Share by Application (2015-2020)
Table 45. Asia Pacific Acute Lymphoblastic Leukemia Drug Sales by Region (2015-2020) (K Pcs)
Table 46. Asia Pacific Acute Lymphoblastic Leukemia Drug Sales Market Share by Region (2015-2020)
Table 47. Asia Pacific Acute Lymphoblastic Leukemia Drug Revenue by Region (2015-2020) (US$ Million)
Table 48. Asia Pacific Acute Lymphoblastic Leukemia Drug Revenue Market Share by Region (2015-2020)
Table 49. Asia Pacific Acute Lymphoblastic Leukemia Drug Sales by Type (2015-2020) (K Pcs)
Table 50. Asia Pacific Acute Lymphoblastic Leukemia Drug Sales Market Share by Type (2015-2020)
Table 51. Asia Pacific Acute Lymphoblastic Leukemia Drug Sales by Application (2015-2020) (K Pcs)
Table 52. Asia Pacific Acute Lymphoblastic Leukemia Drug Sales Market Share by Application (2015-2020)
Table 53. Latin America Acute Lymphoblastic Leukemia Drug Sales by Country (2015-2020) (K Pcs)
Table 54. Latin America Acute Lymphoblastic Leukemia Drug Sales Market Share by Country (2015-2020)
Table 55. Latin Americaa Acute Lymphoblastic Leukemia Drug Revenue by Country (2015-2020) (US$ Million)
Table 56. Latin America Acute Lymphoblastic Leukemia Drug Revenue Market Share by Country (2015-2020)
Table 57. Latin America Acute Lymphoblastic Leukemia Drug Sales by Type (2015-2020) (K Pcs)
Table 58. Latin America Acute Lymphoblastic Leukemia Drug Sales Market Share by Type (2015-2020)
Table 59. Latin America Acute Lymphoblastic Leukemia Drug Sales by Application (2015-2020) (K Pcs)
Table 60. Latin America Acute Lymphoblastic Leukemia Drug Sales Market Share by Application (2015-2020)
Table 61. Middle East and Africa Acute Lymphoblastic Leukemia Drug Sales by Country (2015-2020) (K Pcs)
Table 62. Middle East and Africa Acute Lymphoblastic Leukemia Drug Sales Market Share by Country (2015-2020)
Table 63. Middle East and Africa Acute Lymphoblastic Leukemia Drug Revenue by Country (2015-2020) (US$ Million)
Table 64. Middle East and Africa Acute Lymphoblastic Leukemia Drug Revenue Market Share by Country (2015-2020)
Table 65. Middle East and Africa Acute Lymphoblastic Leukemia Drug Sales by Type (2015-2020) (K Pcs)
Table 66. Middle East and Africa Acute Lymphoblastic Leukemia Drug Sales Market Share by Type (2015-2020)
Table 67. Middle East and Africa Acute Lymphoblastic Leukemia Drug Sales by Application (2015-2020) (K Pcs)
Table 68. Middle East and Africa Acute Lymphoblastic Leukemia Drug Sales Market Share by Application (2015-2020)
Table 69. Otsuka Corporation Information
Table 70. Otsuka Description and Major Businesses
Table 71. Otsuka Acute Lymphoblastic Leukemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 72. Otsuka Product
Table 73. Otsuka Recent Development
Table 74. Ono Pharmaceuticals Corporation Information
Table 75. Ono Pharmaceuticals Description and Major Businesses
Table 76. Ono Pharmaceuticals Acute Lymphoblastic Leukemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 77. Ono Pharmaceuticals Product
Table 78. Ono Pharmaceuticals Recent Development
Table 79. Amgen Corporation Information
Table 80. Amgen Description and Major Businesses
Table 81. Amgen Acute Lymphoblastic Leukemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 82. Amgen Product
Table 83. Amgen Recent Development
Table 84. Bristol-Myers Squibb Corporation Information
Table 85. Bristol-Myers Squibb Description and Major Businesses
Table 86. Bristol-Myers Squibb Acute Lymphoblastic Leukemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 87. Bristol-Myers Squibb Product
Table 88. Bristol-Myers Squibb Recent Development
Table 89. Novartis Corporation Information
Table 90. Novartis Description and Major Businesses
Table 91. Novartis Acute Lymphoblastic Leukemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 92. Novartis Product
Table 93. Novartis Recent Development
Table 94. Boehringer Ingelheim Corporation Information
Table 95. Boehringer Ingelheim Description and Major Businesses
Table 96. Boehringer Ingelheim Acute Lymphoblastic Leukemia Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 97. Boehringer Ingelheim Product
Table 98. Boehringer Ingelheim Recent Development
Table 99. Global Acute Lymphoblastic Leukemia Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 100. Global Acute Lymphoblastic Leukemia Drug Sales Market Share Forecast by Regions (2021-2026)
Table 101. Global Acute Lymphoblastic Leukemia Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 102. Global Acute Lymphoblastic Leukemia Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 103. North America: Acute Lymphoblastic Leukemia Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 104. North America: Acute Lymphoblastic Leukemia Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 105. Europe: Acute Lymphoblastic Leukemia Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 106. Europe: Acute Lymphoblastic Leukemia Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 107. Asia Pacific: Acute Lymphoblastic Leukemia Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 108. Asia Pacific: Acute Lymphoblastic Leukemia Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 109. Latin America: Acute Lymphoblastic Leukemia Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 110. Latin America: Acute Lymphoblastic Leukemia Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 111. Middle East and Africa: Acute Lymphoblastic Leukemia Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 112. Middle East and Africa: Acute Lymphoblastic Leukemia Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 113. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 114. Key Challenges
Table 115. Market Risks
Table 116. Main Points Interviewed from Key Acute Lymphoblastic Leukemia Drug Players
Table 117. Acute Lymphoblastic Leukemia Drug Customers List
Table 118. Acute Lymphoblastic Leukemia Drug Distributors List
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Acute Lymphoblastic Leukemia Drug Product Picture
Figure 2. Global Acute Lymphoblastic Leukemia Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Oral Product Picture
Figure 4. Parenteral Product Picture
Figure 5. Global Acute Lymphoblastic Leukemia Drug Sales Market Share by Application in 2020 & 2026
Figure 6. Hospital
Figure 7. Other medical institutions
Figure 8. Acute Lymphoblastic Leukemia Drug Report Years Considered
Figure 9. Global Acute Lymphoblastic Leukemia Drug Market Size 2015-2026 (US$ Million)
Figure 10. Global Acute Lymphoblastic Leukemia Drug Sales 2015-2026 (K Pcs)
Figure 11. Global Acute Lymphoblastic Leukemia Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 12. Global Acute Lymphoblastic Leukemia Drug Sales Market Share by Region (2015-2020)
Figure 13. Global Acute Lymphoblastic Leukemia Drug Sales Market Share by Region in 2019
Figure 14. Global Acute Lymphoblastic Leukemia Drug Revenue Market Share by Region (2015-2020)
Figure 15. Global Acute Lymphoblastic Leukemia Drug Revenue Market Share by Region in 2019
Figure 16. Global Acute Lymphoblastic Leukemia Drug Sales Share by Manufacturer in 2019
Figure 17. The Top 10 and 5 Players Market Share by Acute Lymphoblastic Leukemia Drug Revenue in 2019
Figure 18. Acute Lymphoblastic Leukemia Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 19. Global Acute Lymphoblastic Leukemia Drug Sales Market Share by Type (2015-2020)
Figure 20. Global Acute Lymphoblastic Leukemia Drug Sales Market Share by Type in 2019
Figure 21. Global Acute Lymphoblastic Leukemia Drug Revenue Market Share by Type (2015-2020)
Figure 22. Global Acute Lymphoblastic Leukemia Drug Revenue Market Share by Type in 2019
Figure 23. Global Acute Lymphoblastic Leukemia Drug Market Share by Price Range (2015-2020)
Figure 24. Global Acute Lymphoblastic Leukemia Drug Sales Market Share by Application (2015-2020)
Figure 25. Global Acute Lymphoblastic Leukemia Drug Sales Market Share by Application in 2019
Figure 26. Global Acute Lymphoblastic Leukemia Drug Revenue Market Share by Application (2015-2020)
Figure 27. Global Acute Lymphoblastic Leukemia Drug Revenue Market Share by Application in 2019
Figure 28. North America Acute Lymphoblastic Leukemia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 29. North America Acute Lymphoblastic Leukemia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 30. North America Acute Lymphoblastic Leukemia Drug Sales Market Share by Country in 2019
Figure 31. North America Acute Lymphoblastic Leukemia Drug Revenue Market Share by Country in 2019
Figure 32. U.S. Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 33. U.S. Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 34. Canada Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 35. Canada Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. North America Acute Lymphoblastic Leukemia Drug Market Share by Type in 2019
Figure 37. North America Acute Lymphoblastic Leukemia Drug Market Share by Application in 2019
Figure 38. Europe Acute Lymphoblastic Leukemia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 39. Europe Acute Lymphoblastic Leukemia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 40. Europe Acute Lymphoblastic Leukemia Drug Sales Market Share by Country in 2019
Figure 41. Europe Acute Lymphoblastic Leukemia Drug Revenue Market Share by Country in 2019
Figure 42. Germany Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 43. Germany Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 44. France Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 45. France Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. U.K. Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. U.K. Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. Italy Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. Italy Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Russia Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. Russia Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Europe Acute Lymphoblastic Leukemia Drug Market Share by Type in 2019
Figure 53. Europe Acute Lymphoblastic Leukemia Drug Market Share by Application in 2019
Figure 54. Asia Pacific Acute Lymphoblastic Leukemia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 55. Asia Pacific Acute Lymphoblastic Leukemia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 56. Asia Pacific Acute Lymphoblastic Leukemia Drug Sales Market Share by Region in 2019
Figure 57. Asia Pacific Acute Lymphoblastic Leukemia Drug Revenue Market Share by Region in 2019
Figure 58. China Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 59. China Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Japan Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 61. Japan Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. South Korea Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. South Korea Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. India Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. India Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. Australia Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. Australia Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Taiwan Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. Taiwan Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Indonesia Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Indonesia Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Thailand Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Thailand Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Malaysia Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Malaysia Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Philippines Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Philippines Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Vietnam Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Vietnam Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Asia Pacific Acute Lymphoblastic Leukemia Drug Market Share by Type in 2019
Figure 81. Asia Pacific Acute Lymphoblastic Leukemia Drug Market Share by Application in 2019
Figure 82. Latin America Acute Lymphoblastic Leukemia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 83. Latin America Acute Lymphoblastic Leukemia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 84. Latin America Acute Lymphoblastic Leukemia Drug Sales Market Share by Country in 2019
Figure 85. Latin America Acute Lymphoblastic Leukemia Drug Revenue Market Share by Country in 2019
Figure 86. Mexico Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 87. Mexico Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 88. Brazil Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 89. Brazil Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Argentina Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Argentina Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Latin America Acute Lymphoblastic Leukemia Drug Market Share by Type in 2019
Figure 93. Latin America Acute Lymphoblastic Leukemia Drug Market Share by Application in 2019
Figure 94. Middle East and Africa Acute Lymphoblastic Leukemia Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 95. Middle East and Africa Acute Lymphoblastic Leukemia Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 96. Middle East and Africa Acute Lymphoblastic Leukemia Drug Sales Market Share by Country in 2019
Figure 97. Middle East and Africa Acute Lymphoblastic Leukemia Drug Revenue Market Share by Country in 2019
Figure 98. Turkey Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 99. Turkey Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 100. Saudi Arabia Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 101. Saudi Arabia Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. U.A.E Acute Lymphoblastic Leukemia Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. U.A.E Acute Lymphoblastic Leukemia Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Middle East and Africa Acute Lymphoblastic Leukemia Drug Market Share by Type in 2019
Figure 105. Middle East and Africa Acute Lymphoblastic Leukemia Drug Market Share by Application in 2019
Figure 106. North America Acute Lymphoblastic Leukemia Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 107. North America Acute Lymphoblastic Leukemia Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 108. Europe Acute Lymphoblastic Leukemia Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 109. Europe Acute Lymphoblastic Leukemia Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 110. Asia Pacific Acute Lymphoblastic Leukemia Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. Asia Pacific Acute Lymphoblastic Leukemia Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Latin America Acute Lymphoblastic Leukemia Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Latin America Acute Lymphoblastic Leukemia Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Middle East and Africa Acute Lymphoblastic Leukemia Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Middle East and Africa Acute Lymphoblastic Leukemia Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Porter's Five Forces Analysis
Figure 117. Channels of Distribution
Figure 118. Distributors Profiles
Figure 119. Bottom-up and Top-down Approaches for This Report
Figure 120. Data Triangulation
Figure 121. Key Executives Interviewed
急性骨髄性白血病の世界市場（～2026年） Leukemia are a heterogeneous group of cancers affecting the bone marrow and White Blood Cells (WBC). Leukemia is characterized by the rapid increase of abnormal blood cells growth or blasts, resulting in a decrease in the numbers of healthy, normal fully modified blood cells, leading to the typical …- 再発急性骨髄性白血病治療薬の世界市場（～2026年） Market Analysis and Insights: Global Relapsed Acute Myeloid Leukemia Drug Market The global Relapsed Acute Myeloid Leukemia Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Relapsed Acute Myeloid Leukemia Drug Scop…
- 急性骨髄性白血病治療薬の世界市場（～2026年） Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90…
- リンパ芽球性リンパ腫治療薬の世界市場（～2026年） Lymphoblastic lymphoma (LL) is a rare type of fast-growing non-Hodgkin lymphoma (NHL). It develops when the body makes abnormal lymphocytes. It can develop from both B-cell and T-cell lymphocytes. Lymphocytes are white blood cells that fight infection. Market Analysis and Insights: Global Lymphoblas…
- 白血病の世界市場（～2026年） Leukemia is a group ofcancers that usually begin in the bone marrow and result in high numbers of abnormal white blood cells. High incidence rate of blood cancers and rise in incidence of leukaemia across the globe will drive the leukemia market. Market Analysis and Insights: Global Leukemia Cancer …